CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
NCT ID: NCT03559439
Last Updated: 2020-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
9 participants
INTERVENTIONAL
2018-04-24
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CD19 CAR T
CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.
CD19 CAR T
CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CD19 CAR T
CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsed or refractory B acute lymphocytic leukemia.
* Relapse was defined as presence of \> 5% blasts at screening, or second or subsequent bone marrow relapse, or any bone marrow relapse after allogeneic stem cell transplant and must be ≥ 6 months from stem cell transplant at the time of infusion.
* Refractory was defined by not achieving an initial complete response after 2 cycles of a standard chemotherapy regimen . Patients who were refractory to subsequent chemotherapy regimens after an initial remission were considered chemorefractory
* Patients with Ph+ acute lymphocytic leukemia were eligible if they are intolerant to or have not achieved a remission after two lines of tyrosine kinase inhibitor therapy, or if tyrosine kinase inhibitor therapy is contraindicated, or ineligible for allogeneic stem cell transplant because of:
* Comorbid disease
* Other contraindications to allogeneic stem cell transplant conditioning regimen
* Lack of suitable donor
* Prior hematopoietic stem cell transplant
* Declined allogeneichematopoietic stem cell transplant as a therapeutic option
* Relapsed or refractory non-Hodgkin's lymphoma
* Histopathological CD19+.
* No response to last line of therapy i. partial response as best response to most recent therapy regimen ii. partial response as best response to most recent therapy with duration no longer than 6 month from last dose of therapy
* Refractory post-Autologous stem cell transplant i. Disease progression or relapsed less than or equal to 12 months of Autologous stem cell transplant (must have biopsy proven recurrence in relapsed subjects) ii. If salvage therapy is given post-Autologous stem cell transplant, the subject must have had no response to or relapsed after the last line of therapy
* Subjects must have received adequate prior therapy including at a minimum: anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative and an anthracycline containing chemotherapy regimen for subjects with transformed follicular lymphoma must have received prior chemotherapy for follicular lymphoma and subsequently have chemorefractory disease after transformation to Diffuse large B-cell lymphoma
* At least one measurable lesion per revised IWG Response Criteria
2. 18-75 years old
3. Expected survival ≥ 12 weeks
4. Adequate renal, hepatic, pulmonary and cardiac function defined as:
* Creatinine clearance (as estimated by Cockcroft Gault) \> 60 mL/min
* Serum ALT/AST \<2.5 ULN
* Total bilirubin \<1.5 mg/dl, except in subjects with Gilbert's syndrome
* Cardiac ejection fraction \>50%, no evidence of pericardial effusion as determined by an echocardiogram, and no clinically significant pleural effusion
* Baseline oxygen saturation \>92% on room air
5. Eastern cooperative oncology group (ECOG) performance status of 0 - 2
6. Pregnant or lactating women must have a negative pregnancy test before infusion, and agree to take effective contraception during the trial
7. Apheresis product received and accepted
8. Written informed consent
Exclusion Criteria
2. Other malignancies
3. Concomitant genetic syndrome, with the exception of Down Syndrome
4. Burkitt's lymphoma/leukemia
5. Treatment with any prior gene therapy product, anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy
6. Active hepatitis B, C, or any uncontrolled infection
7. Grade 2 to 4 Graft versus Host Disease (GVHD)
8. Medications or treatments that were to be excluded:
* Corticosteroids within 72 hours of infusion, with the exception of physiologic replacement
* Allogeneic cellular therapy, such as donor lymphocyte infusion within 6 weeks prior to infusion
* Graft versus Host Disease therapies
* Chemotherapy stopped prior to lymphodepletion based on clearance
* central nervous system prophylaxis treatment
9. Active central nervous system disease (central nervous system 2 disease \[Cerebral spinal fluid containing blasts, but \< 5 WBCs/microliter\] patients were eligible)
10. Any condition that investigator considered may increase the risk of the subjects or interfere with the trial results
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gracell Biotechnology Ltd.
OTHER
Shanghai Tong Ren Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liu Ligen
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ligen Liu
Role: PRINCIPAL_INVESTIGATOR
Shanghai Tong Ren Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Tong Ren hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTA001
Identifier Type: -
Identifier Source: org_study_id